388 related articles for article (PubMed ID: 25668664)
1. Immune-based treatment and prevention of Clostridium difficile infection.
Zhao S; Ghose-Paul C; Zhang K; Tzipori S; Sun X
Hum Vaccin Immunother; 2014; 10(12):3522-30. PubMed ID: 25668664
[TBL] [Abstract][Full Text] [Related]
2. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
[TBL] [Abstract][Full Text] [Related]
3. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Chicken IgY Specific to
Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
[No Abstract] [Full Text] [Related]
5. The prospect for vaccines to prevent Clostridium difficile infection.
Ghose C; Kelly CP
Infect Dis Clin North Am; 2015 Mar; 29(1):145-62. PubMed ID: 25677708
[TBL] [Abstract][Full Text] [Related]
6. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC.
Ghose C; Eugenis I; Sun X; Edwards AN; McBride SM; Pride DT; Kelly CP; Ho DD
Emerg Microbes Infect; 2016 Feb; 5(2):e8. PubMed ID: 26839147
[TBL] [Abstract][Full Text] [Related]
8. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines.
Gerding DN
Discov Med; 2012 Jan; 13(68):75-83. PubMed ID: 22284786
[TBL] [Abstract][Full Text] [Related]
9. New insights for vaccine development against Clostridium difficile infections.
Pizarro-Guajardo M; Chamorro-Veloso N; Vidal RM; Paredes-Sabja D
Anaerobe; 2019 Aug; 58():73-79. PubMed ID: 31034928
[TBL] [Abstract][Full Text] [Related]
10. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
Villafuerte Gálvez JA; Kelly CP
Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
[TBL] [Abstract][Full Text] [Related]
11. The host immune response to Clostridium difficile.
Kelly CP; Kyne L
J Med Microbiol; 2011 Aug; 60(Pt 8):1070-1079. PubMed ID: 21415200
[TBL] [Abstract][Full Text] [Related]
12. Immunization Strategies Against Clostridium difficile.
Bruxelle JF; Péchiné S; Collignon A
Adv Exp Med Biol; 2018; 1050():197-225. PubMed ID: 29383671
[TBL] [Abstract][Full Text] [Related]
13. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
14. Passive and active immunization strategies against Clostridium difficile infections: state of the art.
Mizrahi A; Collignon A; Péchiné S
Anaerobe; 2014 Dec; 30():210-9. PubMed ID: 25079668
[TBL] [Abstract][Full Text] [Related]
15. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.
Wang YK; Yan YX; Kim HB; Ju X; Zhao S; Zhang K; Tzipori S; Sun X
Hum Vaccin Immunother; 2015; 11(9):2215-22. PubMed ID: 26036797
[TBL] [Abstract][Full Text] [Related]
16. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
[TBL] [Abstract][Full Text] [Related]
17. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.
Hutton ML; Cunningham BA; Mackin KE; Lyon SA; James ML; Rood JI; Lyras D
Sci Rep; 2017 Jun; 7(1):3665. PubMed ID: 28623367
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of Clostridium difficile infection.
Dupont HL
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic properties of the surface layer precursor of Clostridium difficile and vaccination assays in animal models.
Bruxelle JF; Mizrahi A; Hoys S; Collignon A; Janoir C; Péchiné S
Anaerobe; 2016 Feb; 37():78-84. PubMed ID: 26505926
[TBL] [Abstract][Full Text] [Related]
20. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
